Browse by regulation1 article · 1 high
21 CFR 211.42
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.42: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
Inspection exposure across the set
- What has FDA cited under 21 CFR 211.42?
- 1 DSRV article cite 21 CFR 211.42. Enforcement cases behind them: FDA Warning Letter 320-26-55 (case 722497) to Henan Lvyuan Pharmaceutical Co., Ltd., March 26, 2026, made public March 31, 2026, citing cross-contamination risks in multi-product API manufacturing. Inspection exposure across them: 1 high.
- What does DSRV recommend for 21 CFR 211.42?
- From the newest article (Multi-Product API Facilities and the Contamination Gap FDA Finds): FDA's question at a multi-product API site is not whether a cleaning SOP exists but whether the facility can prove, with current product-specific evidence for every equipment-product pair, that its controls are calibrated to the product range it runs today. DSRV is decision support, not legal advice; verify against the official source each article names.
In brief
Address this risk
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.42. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.